Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | RAF1 | P04049 | 1/20 | 0.31 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.31 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.31 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8574458 | 0.71 | LMNA (0.35) | LMNACA12CA1CA9POLB | |
| SCHEMBL9622309 | 0.67 | AR (0.31) | — | |
| SCHEMBL8578338 | 0.62 | — | — | |
| SCHEMBL11478927 | 0.61 | CA12 (0.67) | LMNACA12CA1CA9POLB | |
| SCHEMBL3247068 | 0.59 | — | — | |
| SCHEMBL11883244 | 0.59 | L3MBTL1 (0.44) | LMNACA12CA1CA9POLB | |
| SCHEMBL6341570 | 0.58 | TLR9 (0.52) | CA12CA1CA9POLBTP53 | |
| SCHEMBL19680001 | 0.57 | TSHR (0.37) | CA12CA1CA9POLBCA2 | |
| SCHEMBL28376806 | 0.56 | MGLL (0.42) | LMNA | |
| SCHEMBL370611 | 0.56 | KMT2A (0.64) | CA12CA1CA9POLBCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161264-A1 | (AMPAR-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GILGAMESH PHARMACEUTICALS, INC. | 2025-05-22 | — | — | US | claimed |
| WO-2023154450-A2 | (AMPA-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | WO | claimed |
| US-9125898-B2 | Acetam derivatives for pain relief | NEUROTUNE AG (CH) | 2015-09-08 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| JP-2011513246-A | — | — | 2011-04-28 | — | — | JP | claimed |
| CN-102014896-A | Pharmaceutical composition comprising racetam and carnitine and process for its preparation | BIOLAB SANUS FARMACEUTICA LTDA | 2011-04-13 | — | — | CN | claimed |
| US-20110052556-A1 | PHARMACEUTICAL COMPOSITION COMPRISING RACETAM AND CARNITINE AND PROCESS FOR ITS PREPARATION | Biolab Sanus Farmaceutical Ltda (BR) | 2011-03-03 | — | — | US | claimed |
| EP-2262495-A2 | PHARMACEUTICAL COMPOSITION COMPRISING RACETAM AND CARNITINE AND PROCESS FOR ITS PREPARATION | Biolab Sanus Farmacéutica Ltda (BR) | 2010-12-22 | — | — | EP | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| WO-2009105853-A2 | PHARMACEUTICAL COMPOSITION | BIOLAB SANUS FARMACEUTICA LTDA. (BR) | 2009-09-03 | — | — | WO | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-0759750-A4 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1998-05-27 | — | — | EP | claimed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | claimed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | claimed |
| US-4663464-A | Process for the preparation of dihydro-1H-pyrrolizine-3,5-(2H,6H)-dione | WARNER-LAMBERT COMPANY (US) | 1987-05-05 | — | — | US | claimed |
| EP-0048132-B1 | THE USE OF DIHYDRO-1H-PYRROLIZINE-3,5(2H,6H)-DIONE AS A COGNITION ACTIVATOR, PHARMACEUTICAL COMPOSITIONS CONTAINING THAT COMPOUND, AND THE PRODUCTION OF SUCH COMPOSITIONS | WARNER-LAMBERT COMPANY (US) | 1984-08-15 | — | — | EP | claimed |
| US-4372966-A | TREATMENT OF SENILITY, ENHANCING MEMORY, REVERSAL OF AMNESIA CAUSED BY ELECTRIC SHOCK | WARNER-LAMBERT COMPANY (US) | 1983-02-08 | — | — | US | claimed |
| EP-0048132-A2 | The use of dihydro-1H-pyrrolizine-3,5(2H,6H)-dione as a cognition activator, pharmaceutical compositions containing that compound, and the production of such compositions | WARNER-LAMBERT COMPANY (US) | 1982-03-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161264-A1 | (AMPAR-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GRIN2A, GRIN1, GRIN3A | LMNA 4093/4885CA12 4047/4885CA1 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.